

## **Associations between attention-deficit hyperactivity disorder genetic liability and ICD-10 medical conditions in adults: Utilizing electronic health records in a Phenome-Wide Association Study**

Elis Haan, PhD<sup>1,2</sup>, Kristi Krebs, PhD<sup>1</sup>, Urmo Võsa, PhD<sup>1</sup>, Isabell Brikell, PhD<sup>3,4</sup>, Henrik Larsson, PhD<sup>3,5</sup>,  
Estonian Biobank Research Team<sup>1</sup>, Kelli Lehto, PhD<sup>1</sup>

<sup>1</sup> Institute of Genomics, University of Tartu, Tartu, Estonia

<sup>2</sup> Viljandi Hospital, Psychiatric Clinic, Viljandi, Estonia

<sup>3</sup> Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

<sup>4</sup> Department of Biomedicine, Aarhus University, Aarhus, Denmark

<sup>5</sup> School of Medical Sciences, Örebro University, Örebro, Sweden

Corresponding author: Elis Haan, University of Tartu, Institute of Genomics, Riia mnt 23b, Tartu, Estonia, [elis.haan@ut.ee](mailto:elis.haan@ut.ee), tel: +372 737 4039

Running title: ADHD genetic liability and ICD-10 medical conditions

Keywords: Attention-deficit/hyperactivity disorder; polygenic risk scores; Phenome-wide association study; comorbidity; somatic disease; physical disease

Word count: 4000

## Abstract

**Background:** Attention-deficit hyperactivity disorder (ADHD) is often comorbid with other medical conditions in adult patients. However, ADHD is extremely underdiagnosed in adults and little is known about the medical comorbidities in undiagnosed adult individuals with high ADHD liability. In this study we investigated associations between ADHD genetic liability and electronic health record (EHR)-based ICD-10 diagnoses across all diagnostic categories, in individuals without ADHD diagnosis history.

**Methods:** We used data from the Estonian Biobank cohort (N=111,261) and generated polygenic risk scores (PRS) for ADHD (PRS<sub>ADHD</sub>) based on the latest ADHD genome-wide association study. We performed a phenome-wide association study (PheWAS) to test for associations between standardized PRS<sub>ADHD</sub> and 1,515 EHR-based ICD-10 diagnoses in the full and sex-stratified sample. We compared the observed significant ICD-10 associations to associations with: 1) ADHD diagnosis and 2) questionnaire-based high ADHD risk analyses.

**Results:** After Bonferroni correction ( $p=3.3 \times 10^{-5}$ ) we identified 80 medical conditions associated with PRS<sub>ADHD</sub>. The strongest evidence was seen with chronic obstructive pulmonary disease (OR=1.15, CI=1.11-1.18), obesity (OR=1.13, CI=1.11-1.15), and type 2 diabetes (OR=1.11, CI=1.09-1.14). Sex-stratified analysis generally showed similar associations in males and females. Out of all identified associations, 40% and 78% were also observed using ADHD diagnosis or questionnaire-based ADHD, respectively, as the predictor.

**Conclusions:** Overall our findings indicate that ADHD genetic liability is associated with an increased risk of a substantial number of medical conditions in undiagnosed individuals. These results highlight the need for timely detection and improved management of ADHD symptoms in adults.

## Introduction

Attention-deficit hyperactivity disorder (ADHD) is a highly heritable common neurodevelopmental disorder with a worldwide prevalence of about 5% among school-aged children (1). Although the onset of ADHD is typically in childhood, ADHD often persists in adulthood. It has been shown that at least 15% of children with ADHD meet diagnostic criteria for ADHD also in adulthood. (2). The average prevalence of ADHD in adults has been found to be 3-4% (3). However, ADHD in adults is often underdiagnosed and/or untreated, which may lead to negative psychosocial and health consequences (4). Evidence from previous studies have shown substantial comorbidity between ADHD and both psychiatric and somatic medical conditions, such as hypertension, migraine, obesity and type 2 diabetes, in adulthood (5–7). Yet, the comorbidities in undiagnosed or subclinical ADHD populations are far less clear.

Although shared genetic factors have been implicated in explaining the link between ADHD and psychiatric outcomes (5), little is known about the role of shared genetic mechanisms in ADHD and medical conditions. ADHD is highly heritable with an average heritability of 76% in twin studies (8,9) and SNP-heritability of 22%, based on the latest genome-wide association study (GWAS) of ADHD (10). The genetic correlations based on the results of this ADHD GWAS showed significant genetic overlap between ADHD and several mental health (e.g. depression, subjective well-being and neuroticism), as well as physical health traits and conditions (such as body mass index (BMI), obesity, HDL cholesterol and type 2 diabetes) (10). Another approach to investigate shared genetics across traits and disorders is by using polygenic risk scores (PRSs), which capture an individuals weighted sums of risk alleles as detected with a large-scale, independent GWAS (11). The PRS approach is also useful for identifying individuals with a high genetic liability to complex disorders (12). Currently, PRS for ADHD ( $PRS_{ADHD}$ ) based on the latest GWAS explains up to 5.5% of variance in ADHD and individuals in the top 10% of this PRS show 5 times higher odds of ADHD compared to individuals in

the lowest PRS decile (Demontis et al., 2019). This indicates that PRS<sub>ADHD</sub> has great potential to identify individuals with high ADHD genetic liability in populations with low ADHD prevalence, e.g. due to underdiagnosis.

Despite the strong advantage of exploiting electronic health records (EHR) in medical genetics research in biobanks (13) there are currently few available reports on the associations between PRS<sub>ADHD</sub> and EHR-based medical diagnoses. Previous studies using PRS<sub>ADHD</sub> have mainly focused only on selected physical health diagnoses, but we are currently lacking studies which systematically assess the PRS<sub>ADHD</sub> for associations across all diagnostic categories. Such studies would help to unravel the shared genetic mechanisms underlying the broad comorbidity seen in ADHD in clinical and epidemiological studies. A phenome-wide association study (PheWAS) is a hypothesis-free approach that can be used to test associations between a single predictor (e.g. genetic variants, PRS, diagnosis) and a wide range of phenotypes, such as the EHR data (14). A recent PheWAS based on UK Biobank data showed that PRS<sub>ADHD</sub> was associated with several health related traits (e.g. physical abuse, younger age at first sexual intercourse, smoking behaviour, as well as obesity, higher BMI and several blood measures) (15). Although this study included over 20,000 health-related items, the medical health records of the participants were not systematically analysed since medical health record linkages in UK Biobank were not complete.

We aimed to take the hypothesis-free PheWAS approach in a large population-based biobank (Estonian Biobank; EstBB) to investigate the associations between ADHD genetic liability and lifetime history of medical conditions based on ICD-10 diagnoses from EHRs in individuals without a history of ADHD diagnosis (PRS<sub>ADHD</sub> analysis).

Considering the sex differences in the prevalence of ADHD (16,17), we also investigated potential sex differences for the associations between PRS<sub>ADHD</sub> and medical conditions. Additionally, we compared the direction and strength of the identified ICD-10 associations that passed multiple

correction to the associations between these medical conditions and EHR-based ADHD diagnosis (ADHD diagnosis analysis) as well as to the high ADHD risk based on an adult ADHD brief screening instrument (questionnaire-based ADHD analysis). Although existing evidence shows substantial comorbidity between ADHD and depression, as well as depression and other medical conditions (18–21), it is unknown to what degree depression may mediate ADHD-medical condition link in adults. Therefore, our secondary aim was to explore mediation effect by depression in the identified PRS – medical condition associations.

## Methods and Materials

### Study Population

The Estonian Biobank (EstBB) is a large data-rich population-based biobank (22), covering approximately 20% of the adult population in Estonia (N=~210,000; 66% females; mean birth year 1971). All EstBB participants have signed an informed consent form and provided blood samples for genotyping and the EHR data is regularly retrieved by linking to the national health databases and registries, such as the National Health Insurance Funds (NHIF) database, cause of death register, and hospital records. Estonia has universal health care, covering more than 95% of the population. The research project has obtained approval from the Estonian Council on Bioethics and Human Research. More details about the recruitment of participants can be found in Supplementary information.

### Phenotype data

#### ***Medical conditions via ICD-10 diagnoses***

Medical diagnosis data was drawn from the EHRs based on the NHIF's database covering the period from 2004 to 2020. NHIF's database is a nationwide system integrating data from all healthcare providers in Estonia. EHR data included 2,004 ICD-10 codes, of which 489 were excluded as these were not medical diagnoses or were in a very low prevalence (Table S1). In total, 1,515 phenotypes from all ICD-10 disease categories (Table S2) were included in the analyses. ADHD diagnosis was defined by ICD-10 diagnosis code F90 (including diagnoses F90.0, F90.1, F90.8 and F90.9).

#### ***High ADHD risk based on Adult ADHD Self-Report Scale***

As a sensitivity analysis, we included self-reported ADHD symptoms score, measured with the modified Estonian version of Adult ADHD Self-Report Scale (ASRS v1.1) part A (23). ASRS part A is a brief six-item screening questionnaire and items are assessed on Likert scale ranging from 0-4:

0=never; 1=rarely; 2=sometimes; 3=often; 4=very often. A score cutoff of 14 out of 24 represents individuals with higher risk for ADHD (24). ASRS data in EstBB is available for 86,245 participants.

### ADHD polygenic risk scores

For computing the PRS, the PRS-CS-auto algorithm was first used to apply a Bayesian regression framework to infer posterior effect sizes of SNPs by using the largest available ADHD GWAS summary statistics (10) and an external linkage disequilibrium reference panel (25). Per-individual risks were further calculated with plink 2.0 (26). The PRS<sub>ADHD</sub> was standardized for the PheWAS analysis and categorized into deciles for subsequent analyses to test differences in high vs low/middle genetic liability groups. Prior to the main analysis, we tested the association between PRS<sub>ADHD</sub> and ICD-10 ADHD diagnosis history. The variance explained by the PRS<sub>ADHD</sub> was computed by subtracting the Nagelkerke pseudo R<sup>2</sup> from the full (PRS, birth year, recruitment year, sex and 10 PCs) and the reduced (birth year, recruitment year, sex and 10 PCs) logistic regression models. Details about the genotyping and imputation procedures in the EstBB can be found in Supplementary information.

### Statistical analysis

#### **Main analysis**

PheWAS was implemented to test for the associations between PRS<sub>ADHD</sub> and 1,515 ICD-10 main diagnosis codes in the undiagnosed subsample where all individuals with a history of ADHD diagnosis (F90\*) were removed (N=464). Analyses were performed as described in our pre-registered protocol (27). PheWAS was conducted using logistic regression adjusted for sex (except in sex-stratified analyses), birth- and recruitment year to adjust for birth cohort effects and different EstBB recruitment strategies used across two decades, and 10 genetic principal components to adjust for genetic ancestry. Relatedness within the sample was handled by excluding related individuals (PI-HAT>0.2; 85,708 out of 196,969 participants were removed). However, for comparison we ran the

main analyses in the full cohort without excluding related individuals (N=196,935). Correction for multiple testing was done by applying Bonferroni correction (p-value threshold  $3.3 \times 10^{-5}$ ). PheWAS and mediation analyses were run in R (version 3.6.0) and PheWAS results were visualised using the PheWAS library <https://github.com/PheWAS/PheWAS>. Other analyses were performed using Stata v.17.

### **PRS<sub>ADHD</sub> deciles**

We further examined the associations that survived the multiple testing correction in the PheWAS by using PRS<sub>ADHD</sub> deciles (ranging from 10<sup>th</sup> to 90<sup>th</sup> percentiles) to explore the difference in the odds of being diagnosed with a specific medical condition in high vs low (10<sup>th</sup> vs 1<sup>st</sup> PRS decile) and in high vs middle (10<sup>th</sup> vs 5<sup>th</sup> PRS decile) ADHD genetic liability groups. While the difference in the top and bottom genetic liability groups reflects the differences between the two extreme ends of ADHD genetic liability, the top versus middle comparison reflects the differences between the highest and the population average ADHD genetic liability groups. Additionally, we explored sex differences in the top and bottom PRS decile analysis. These analyses were conducted using logistic regression, adjusted for sex, birth- and recruitment year, and 10 genetic principal components.

### Secondary analyses

#### **Comparison of effects across PRS<sub>ADHD</sub>, ADHD diagnosis and questionnaire-based ADHD analyses**

To shed light on the different patterns in medical condition risk in biobank participants with high ADHD genetic liability but without an ADHD diagnosis, lifetime ADHD diagnosis and clinically relevant ADHD symptoms, we conducted two sets of additional logistic regression analyses only on these medical outcomes that passed the multiple testing correction in the PRS<sub>ADHD</sub> PheWAS analyses. First, we used the EHR-based lifetime ADHD diagnosis as the predictor and second, we used the questionnaire-based high ADHD risk as the predictor. In both cases, the analyses were adjusted for sex, birth- and recruitment year.



### **Causal mediation analysis with depression diagnosis**

Considering the well-established link between depression, ADHD and worse physical health conditions, we ran causal mediation analysis for the identified phenotypes and included lifetime depressive episode diagnosis as a mediator. Lifetime depressive episode diagnosis was defined based on the ICD-10 diagnosis codes F32\* and F33\*. Causal mediation analysis was run using the R package mediation and 1000 simulations was used for calculating estimates (28).

## Results

A descriptive overview of the study samples is shown in Table 1. The main analysis study sample (PRS<sub>ADHD</sub>) size was 111,261 individuals, after exclusion of related individuals (N=85,708), ADHD cases (N=464), and individuals with missing EHR records (N=2,887). 65% of the study sample were female and the mean birth year was 1970. In the ADHD diagnosis analysis sample, the sample size was 111,601, of which 464 were diagnosed ADHD cases (0.5%). In the questionnaire-based ADHD sample, 3,556 participants screened positive for high risk for ADHD (8%). Cross-group comparisons indicate that although the female-male ratio was similar in all three samples, individuals in the ADHD diagnosis analysis sample were considerably younger (mean birth year 1990) compared to the two other study samples (mean birth year 1970 for PRS<sub>ADHD</sub> analysis sample and 1979 for questionnaire-based ADHD analysis sample).

### PheWAS of PRS<sub>ADHD</sub>

First, we tested the association of the PRS<sub>ADHD</sub> with ADHD diagnosis (OR=1.34, CI=1.22-1.47) and questionnaire-based ADHD (OR=1.06, CI=1.02-1.09). Results indicate that 1 SD increase in PRS<sub>ADHD</sub> corresponds to 34% increase in the odds of ADHD diagnosis and 6% increase in the odds of higher risk for self-reported questionnaire-based ADHD. PRS<sub>ADHD</sub> explained 0.6% variance in EHR-based ADHD diagnosis and 0.04% in questionnaire-based high-risk ADHD.

Our PheWAS showed evidence of association between PRS<sub>ADHD</sub> and for 80 ICD-10 diagnoses after correction for multiple testing (Figure 1, Table S3). Overall, the top five medical conditions with the strongest evidence for associations were chronic obstructive pulmonary disease (COPD) (OR=1.15, CI=1.11-1.18), obesity (OR=1.13, CI=1.11-1.15), type 2 diabetes (OR=1.11, CI=1.09-1.14), dorsalgia (OR=1.08, CI=1.07-1.10), and polyarthrosis (OR=1.09, CI=1.07-1.12).

Sex-stratified analyses showed that for females, the top five associated medical conditions were obesity (OR=1.14, CI=1.11-1.16), polyarthrosis (OR=1.10, CI=1.08-1.13), medical abortion (OR=1.10, CI=1.08-1.13), dorsalgia (OR=1.09, CI=1.07-1.09), and headache (OR=1.08, CI=1.06-1.10). For males, the top five associated medical conditions were COPD (OR=1.17, CI=1.12-1.23), mental and behavioural disorders due to use of alcohol (OR=1.11, CI=1.07-1.15), obesity (OR=1.11, CI=1.07-1.15), type 2 diabetes (OR=1.10, CI=1.06-1.14), and dorsalgia (OR=1.07, CI=1.04-1.09). Full results are shown in Table S4 and Figures S1-S2.

The results in the full cohort (relatives not excluded) were largely similar, but additionally 52 associations passed correction for multiple testing potentially due to larger sample size and non-independence between observations (Table S5).

#### PRS<sub>ADHD</sub> deciles

The PRS<sub>ADHD</sub> decile analysis of the 80 significantly associated medical conditions showed that individuals in the top PRS<sub>ADHD</sub> decile had 70% higher risk for COPD (OR=1.70; CI=1.48-1.95); 59% higher risk for obesity (OR=1.59; CI=1.47-1.73), 51% higher risk for toxic effects of alcohol (OR=1.51; CI=1.16-1.97), 45% higher risk for type 2 diabetes (OR=1.45; CI=1.30-1.61), and 34% higher risk for polyarthrosis (OR=1.34, CI=1.23-1.47), compared to individuals in the lowest PRS<sub>ADHD</sub> decile. The results using top vs middle PRS<sub>ADHD</sub> decile were mostly in line with the results from top vs bottom PRS<sub>ADHD</sub> decile analysis, but were non-significant for 23 medical conditions, e.g. other sexually transmitted diseases, heart failures, atherosclerosis, acute bronchitis, other arthritis and pregnancy related phenotypes (Figure 2; Tables S6-S7). The results comparing the high PRS<sub>ADHD</sub> group separately in females and males are shown in Figure 3 and Tables S8-S9. 11 phenotypes were only available in females (such as pregnancy-related conditions). The majority of the associations in females and males were in the same direction. Of the phenotypes that were available in both gender 15 associations were significant only in females (including, cystitis, cholelithiasis, gastro-oesophageal reflux disease (GORD), migraine, gastric ulcer, other arthrosis, other joint disorders, other

spondylopathies, abdominal and pelvic pain and other sexually transmitted disease (STD) diagnoses). In contrast, associations with personality and behavioural disorders due to brain damage and dysfunction, toxic effects of alcohol and cardiac and vascular implants and grafts were only significantly associated in males.

## Secondary analyses

### Comparison of effects across PRS<sub>ADHD</sub>, ADHD diagnosis and questionnaire-based ADHD analyses

In the ADHD diagnosis analysis, 18 medical conditions had insufficient case numbers (<10 cases) to be included in these analyses (Table S10). We observed significant associations between ADHD diagnosis and 31 medical conditions, of which 6 medical conditions showed protective associations (for example other STDs, melanocytic nevus, excessive and irregular menstruation, medical abortion and pregnancy related conditions) (Figure 4). Overall, 40% of the PRS<sub>ADHD</sub> associations were also observed in the ADHD diagnosis analysis. We observed the strongest evidence for associations with psychiatric disorders, e.g. behavioural disorders due to brain disease (OR=6.42, CI=4.08-10.11), reaction to severe stress (OR=4.70, CI=3.83-5.76), recurrent depressive disorders (OR=3.97, CI=3.08-5.11), but also with asthma (OR=2.11, CI=1.64-2.70) and acute bronchitis (OR=1.72, CI=1.43-2.06).

In the questionnaire-based ADHD analysis, the direction of the effects were largely similar as in the PRS decile analysis and 78% of the PRS<sub>ADHD</sub> associations were observed in the questionnaire-based ADHD analysis. We observed the strongest evidence for associations with recurrent depressive disorders (OR=3.78, CI=3.44-4.16), anxiety disorders (OR=2.31, CI=2.14-2.50), polyarthrosis (OR=1.94, CI=1.70-2.20), sleep disorders (OR=1.94, CI=1.77-2.13), and asthma (OR=1.64, CI=1.48-1.81). These results are shown in Figure 4, and Tables S10-S11.

### Causal mediation analysis

Our findings from causal mediation analysis showed that depression was a significant mediator for all 78 medical conditions (two depression diagnoses were excluded from the analyses), but the

proportion of the effect between PRS<sub>ADHD</sub> and medical conditions that was mediated by depression for majority of outcomes was generally small, ranging from 2 to 16%. Only for mental disorders, such as sleep disorders, anxiety disorders, reaction to severe stress and mental disorders due to brain damage and dysfunction, the mediation effect accounted for more than 20% of the observed associations between PRS<sub>ADHD</sub> and respective ICD-10 diagnosis (Table S12).

## Discussion

In this study we performed a PheWAS between PRS<sub>ADHD</sub> and EHR-based diagnoses across all ICD-10 categories, using nationwide, population representative clinical data with up to 17 years follow-up. This approach enabled the investigation of the associations between genetic liability to ADHD and medical conditions in a population without a history of ADHD diagnosis. Overall, our results indicate robust associations between ADHD genetic liability and 80 medical conditions, with obesity, dorsalgia, polyarthrosis, COPD and type 2 diabetes among the top associated medical conditions.

These results are generally in line with previous findings on the associations between ADHD diagnosis and comorbid medical conditions (29,30). Furthermore, similarly to our findings, a study conducted on UK Biobank data (15) also showed associations between PRS<sub>ADHD</sub>, mental and physical health problems, indicating a shared genetic background between ADHD and medical conditions. Another large-scale genetic study, also based on UK Biobank data, found that genetic liability to multiple complex traits as an adult, such as type 2 diabetes, obesity, peripheral artery disease and polyarthritis, increases the risk for ADHD as a child, which further shows the role of underlying genetic effects between physical health and ADHD across development (31).

Several of the observed associations between PRS<sub>ADHD</sub> and medical conditions in non-diagnosed individuals are consistent with the few previous genetically informative studies on diagnosed ADHD and medical comorbidities, such as the nervous system (29), respiratory (29,31), musculoskeletal (29) and cardiometabolic diseases (29,32). A study, based on a twin design, demonstrated that some of the observed associations between medical conditions and ADHD diagnosis were mediated by lifestyle factors, such as tobacco use and alcohol misuse (32). Therefore, it is also possible that the associations observed in our study could be mediated by lifestyle factors, although this requires further investigation in future studies. By using the causal mediation analysis, we found that

depression was a significant mediator for all observed medical conditions, but the effect from depression alone was rather small. Given the high comorbidity and genetic correlation between ADHD and depression, these results are expected. However, it is also possible that adults with undiagnosed or subclinical ADHD, potentially expressing symptoms that may overlap with depression (e.g. concentration problems, inattention), may be more likely diagnosed with depression, which may lead to misclassification bias and affect observed findings.

A recent Mendelian Randomization study showed a bidirectional causal effect between ADHD and obesity-related traits (e.g. waist-hip-ratio (WHR) and BMI-adjusted WHR) and reported genetic overlap between BMI and ADHD (33). It has been also shown that obesity increases the risk for a chronic inflammatory state (34), which can lead to several diseases, such as hypertension, type 2 diabetes, cardiovascular disease, and musculoskeletal diseases (35,36). There is also some evidence that inflammation plays an important role in the aetiology of ADHD (37). It has been reported that individuals with ADHD had an increased inflammatory marker interleukin 6 (IL-6) which has been linked with increased risk of diabetes (38,39). Similarly, the role of obesity and inflammation markers are well described in the aetiology of cholelithiasis and GORD (40,41). Therefore, it is plausible that obesity can act as a mediator on the pathway between ADHD and several medical conditions, a hypothesis which needs more research in future studies. In fact, the study by Garcia-Argibay and colleagues found that BMI mediated associations between  $PRS_{ADHD}$  and medical conditions like hypertension, type 2 diabetes, migraine and sleep disorders (32).

The sex-stratified analysis generally showed similar associations in males and females. Several conditions that were statistically significant only in one gender (e.g. diseases of the musculoskeletal and digestive system, personality and behavioural disorders due to brain damage and dysfunction, toxic effects of alcohol and cardiac and vascular implants and grafts), we observed similar effect sizes in both genders, potentially indicating insufficient case numbers in the sex-stratified analyses.

However, we also observed some sex differences. The association with sexually transmitted chlamydial diseases was more strongly associated in females. The literature supports the link between ADHD and risky sexual behaviour. Several studies have shown that ADHD is associated with earlier sexual debut, higher risk of sexually transmitted diseases and more and younger age at first pregnancies (42,43). The study by Leppert and colleagues (15) also demonstrated the association between  $PRS_{ADHD}$  and younger age at first sexual intercourse in the UK Biobank. Although, the prevalence of chlamydia is similar in females and males, the disease is more often asymptomatic in males. Considering that women are more frequently screened in a routine gynaecological care, it is possible that the stronger association observed in females can be explained by higher likelihood of receiving a diagnosis (44). Other associations observed more strongly in females were with cystitis, migraine, cholelithiasis, abdominal and pelvic pain and GORD diagnoses. Cystitis, migraine, abdominal and pelvic pain and cholelithiasis have been reported to be more common in women, which has been suggested to be explained by female hormones and inflammation processes (41,45–47). However, although GORD symptoms are equally prevalent in males and females (40), it has been suggested that oestrogen may mediate the association in females (48).

Our results suggest that ADHD-related medical conditions are also present in individuals without ADHD diagnosis but who have high genetic liability for ADHD. This highlights the importance of improving screening and management of ADHD in adult populations, in order to reduce the risk of severe physical comorbidities in individuals with subclinical or currently undiagnosed ADHD. Although 95% of Estonian residents are covered by universal health care system, providing free or very low-cost access to medical care, ADHD medications for adults are not currently covered by the national health insurance plan in Estonia. This may partly explain the low ADHD prevalence in EstBB (0,5% lifetime prevalence) and in Estonia overall (yearly prevalence of 0,8% in 2015-2020). However, other evidence suggests that ADHD in adults is likely underdiagnosed and undertreated across



countries (49). This is also supported by our findings of the ADHD screening questionnaire, which revealed that 8,7% of the participants have high ADHD risk.

### *Strengths and limitations*

The major strength of this study is inclusion of medical conditions across all ICD-10 diagnoses codes based on EHR with 17 years of follow-up, as well as combining genetic data with EHR and questionnaire data. EHR data is, as compared to self-reported data, not affected by recall bias and has better validity for many diagnoses as information is collected prospectively. Furthermore, we used data from a population-based biobank with a large sample size and high coverage of the whole population, thereby improving our statistical power to detect associations of even small effects.

However, this study also has some limitations. First, although EHR are a comprehensive data source, it only includes individuals with more severe symptoms and/or diseases who have received medical treatment. This may lead to misclassification bias, particularly in psychiatric categories, given the low EHR-based ADHD prevalence in EstBB. However, ADHD is often underdiagnosed in middle age and older adults because ADHD in adulthood has been recognized fairly recently (50). Second, population-based cohort studies may be affected by selection bias as healthier and better educated people are more likely to participate in health studies (51). The “healthy volunteer” selection bias has been previously described in the UK Biobank (52) and may also exist in the EstBB. Third, given the small number of ADHD cases in our sample, we could not test the effect of ADHD medications on the results. It is well reported that ADHD drug treatment can help to reduce various negative health outcomes and decrease risk of risky behaviour (53). It is possible that the protective and statistically non-significant associations observed with some phenotypes in the ADHD diagnosis analysis could be affected by treatment effects. However, it is also plausible that individuals with ADHD diagnosis in the EstBB differ substantially from the average individual with ADHD diagnosis due to selection bias. Fourth, since the ADHD diagnosis analytical sample had higher mean birth year, the observed

findings may have been affected by underestimation of associations as some diseases typically emerge in older age.

### *Conclusion*

Our study showed that genetic liability for ADHD is associated with increased risk for various medical conditions in individuals without ADHD diagnosis history. The results largely mirror the known associations between diagnosed ADHD and physical disease comorbidities. Although PheWAS design does not allow to conclude which of the observed associations are causal, it provides insights for future studies to further investigate potential pathways behind these associations. Better knowledge about mechanisms explaining these associations can have a significant public health impact, as better detection and timely management of ADHD symptoms may help to reduce the risks for adverse medical conditions across the life span.

## **Acknowledgements**

We thank all participants and staff of the Estonian biobank for their contribution to this research.

The analytical work of EstBB was carried out in part in the High Performance Computing Center of the University of Tartu. We also thank Liisi Panov from the National Institute for Health Development for providing country-wide ADHD prevalence estimates and Silva Kasela for helping with causal mediation analysis.

Estonian Biobank Research Team: Andres Metspalu, Lili Milani, Tõnu Esko, Reedik Mägi, Mari Nelis and Georgi Hudjashov

This research in the Estonian Biobank was supported by the European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012), and the Estonian Research Council's grant No. PSG615. This study was also funded by EU H2020 grant 692145, Estonian Research Council Grant IUT20-60, IUT24-6, and European Union through the European Regional Development Fund Project No. 2014-2020.4.01.15-0012 GENTRANSMED and 2014-2020.4.01.16-0125. This research is also part of the TIMESPAN project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 965381. This reflects only the author's view, and the European Commission is not responsible for any use that may be made of the information it contains. Henrik Larsson acknowledge financial support from the Swedish Research Council (2018-02599) and the Swedish Brain Foundation (FO2021-0115). Isabell Brikell acknowledges financial support by the Swedish Brain Foundation.

This work has been presented as a poster presentation ("Phenome-wide association study between ADHD polygenic risk and ICD-10 diagnosis codes in the Estonian Biobank") at the World Congress of Psychiatric Genetics in 2021. Preprint of this manuscript is available in medRxiv.

## **Financial Disclosures**

Henrik Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; and sponsorship for

It is made available under a [CC-BY 4.0 International license](#) .

a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. All other authors report no conflicts of interest.

## References

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The Worldwide Prevalence of ADHD: A Systematic Review and Meta-regression Analysis. *Am J Psychiatry*. 2007;7.
2. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. *Psychol Med*. 2006 Feb;36(2):159–65.
3. Fayyad J, Graaf RD, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. *Br J Psychiatry*. 2007 May;190(5):402–9.
4. Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of Attention-Deficit/Hyperactivity Disorder in Adult Patients: A Review of the Literature. *Prim Care Companion CNS Disord*. 2014;16(3):PCC.13r01600.
5. Brikell I, Burton C, Mota NR, Martin J. Insights into attention-deficit/hyperactivity disorder from recent genetic studies. *Psychol Med*. 2021;1–13.
6. Chen Q, Hartman CA, Haavik J, Harro J, Klungsoyr K, Hegvik TA, et al. Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study. *PLoS One*. 2018;13(9):e0204516.
7. Kittel-Schneider S, Arteaga-Henriquez G, Vasquez AA, Asherson P, Banaschewski T, Brikell I, et al. Non-mental diseases associated with ADHD across the lifespan: Fidgety Philipp and Pippi Longstocking at risk of multimorbidity? *Neurosci Biobehav Rev*. 2022 Jan 1;132:1157–80.
8. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2005 Jun 1;57(11):1313–23.
9. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. *Mol Psychiatry*. 2019 Apr;24(4):562–75.
10. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat Genet*. 2019 Jan;51(1):63–75.
11. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. *Genome Med*. 2020 May 18;12(1):44.
12. Murray GK, Lin T, Austin J, McGrath JJ, Hickie IB, Wray NR. Could Polygenic Risk Scores Be Useful in Psychiatry?: A Review. *JAMA Psychiatry*. 2021 Feb 1;78(2):210–9.
13. Abul-Husn NS, Kenny EE. Personalized Medicine and the Power of Electronic Health Records. *Cell*. 2019 Mar 21;177(1):58–69.
14. Pendergrass S a., Brown-Gentry K, Dudek S m., Torstenson E s., Ambite J l., Avery C l., et al. The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery. *Genet Epidemiol*. 2011;35(5):410–22.

15. Leppert B, Millard LAC, Riglin L, Davey Smith G, Thapar A, Tilling K, et al. A cross-disorder PRS-pheWAS of 5 major psychiatric disorders in UK Biobank. *PLoS Genet*. 2020 May 11;16(5):e1008185.
16. Biederman J, Faraone SV, Monuteaux MC, Bober M, Cadogen E. Gender effects on Attention-Deficit/Hyperactivity disorder in adults, revisited. *Biol Psychiatry*. 2004 Apr 1;55(7):692–700.
17. Gaub M, Carlson CL. Gender Differences in ADHD: A Meta-Analysis and Critical Review. *J Am Acad Child Adolesc Psychiatry*. 1997 Aug 1;36(8):1036–45.
18. Carney RM, Freedland KE. Depression in patients with coronary artery disease: a more significant problem than previously recognized? *Eur Heart J - Qual Care Clin Outcomes*. 2017 Oct 1;3(4):262–3.
19. Kan C, Pedersen NL, Christensen K, Bornstein SR, Licinio J, MacCabe JH, et al. Genetic overlap between type 2 diabetes and depression in Swedish and Danish twin registries. *Mol Psychiatry*. 2016 Jul;21(7):903–9.
20. Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. *BMC Psychiatry*. 2017 Aug 22;17(1):302.
21. Rajan S, McKee M, Rangarajan S, Bangdiwala S, Rosengren A, Gupta R, et al. Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. *JAMA Psychiatry*. 2020 Oct 1;77(10):1052–63.
22. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Sieder H, et al. Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. *Int J Epidemiol*. 2015 Aug;44(4):1137–47.
23. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. *Psychol Med*. 2005 Feb;35(2):245–56.
24. Kessler RC, Adler LA, Gruber MJ, Sarawate CA, Spencer T, Van Brunt DL. Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. *Int J Methods Psychiatr Res*. 2007 May 14;16(2):52–65.
25. Ge T, Chen CY, Ni Y, Feng YCA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun*. 2019 Apr 16;10(1):1776.
26. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *GigaScience*. 2015 Dec 1;4(1):s13742-015-0047–8.
27. Haan E, Krebs K, Võsa U, Lehto K. Investigating the electronic health record-based somatic comorbidities in ADHD: using ADHD polygenic risk and ADHD diagnosis-based Phenome-Wide Association Study. 2021 Aug 31 [cited 2022 Mar 22]; Available from: <https://osf.io/7txg2>
28. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal Mediation Analysis. *J Stat Softw*. 2014 Sep 2;59:1–38.
29. Du Rietz E, Brikell I, Butwicka A, Leone M, Chang Z, Cortese S, et al. Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study. *Lancet Psychiatry*. 2021 Sep 1;8(9):774–83.

30. Momen NC, Plana-Ripoll O, Agerbo E, Benros ME, Børghlum AD, Christensen MK, et al. Association between Mental Disorders and Subsequent Medical Conditions. *N Engl J Med*. 2020 Apr 30;382(18):1721–31.
31. García-Marín LM, Campos AI, Kho PF, Martin NG, Cuéllar-Partida G, Rentería ME. Phenome-wide screening of GWAS data reveals the complex causal architecture of obesity. *Hum Genet*. 2021 Aug 1;140(8):1253–65.
32. Garcia-Argibay M, du Rietz E, Lu Y, Martin J, Haan E, Lehto K, et al. The role of ADHD genetic risk in mid-to-late life somatic health conditions. *Transl Psychiatry*. 2022 Apr 11;12(1):1–9.
33. Karhunen V, Bond TA, Zuber V, Hurtig T, Moilanen I, Järvelin MR, et al. The link between attention deficit hyperactivity disorder (ADHD) symptoms and obesity-related traits: genetic and prenatal explanations. *Transl Psychiatry*. 2021 Sep 4;11(1):1–8.
34. Andersen CJ, Murphy KE, Fernandez ML. Impact of Obesity and Metabolic Syndrome on Immunity. *Adv Nutr*. 2016 Jan 1;7(1):66–75.
35. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. *Nat Med*. 2019 Dec;25(12):1822–32.
36. Nikiphorou E, Fragoulis GE. Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review. *Ther Adv Musculoskelet Dis*. 2018 Aug 1;10(8):157–67.
37. Dunn GA, Nigg JT, Sullivan EL. Neuroinflammation as a Risk Factor for Attention Deficit Hyperactivity Disorder. *Pharmacol Biochem Behav*. 2019 Jul;182:22–34.
38. Donfrancesco R, Nativio P, Di Benedetto A, Villa MP, Andriola E, Melegari MG, et al. Anti-Yo Antibodies in Children With ADHD: First Results About Serum Cytokines. *J Atten Disord*. 2020 Sep;24(11):1497–502.
39. Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care*. 2013 Jan;36(1):166–75.
40. El-Serag H. Role of obesity in GORD-related disorders. *Gut*. 2008 Mar 1;57(3):281–4.
41. Littlefield A, Lenahan C. Cholelithiasis: Presentation and Management. *J Midwifery Womens Health*. 2019;64(3):289–97.
42. Hechtman L, Swanson JM, Sibley MH, Stehli A, Owens EB, Mitchell JT, et al. Functional Adult Outcomes 16 Years After Childhood Diagnosis of Attention-Deficit/Hyperactivity Disorder: MTA Results. *J Am Acad Child Adolesc Psychiatry*. 2016 Nov 1;55(11):945-952.e2.
43. Hosain GMM, Berenson AB, Tennen H, Bauer LO, Wu ZH. Attention Deficit Hyperactivity Symptoms and Risky Sexual Behavior in Young Adult Women. *J Womens Health*. 2012 Apr;21(4):463–8.
44. Dielissen PW, Teunissen DA, Lagro-Janssen AL. Chlamydia prevalence in the general population: is there a sex difference? a systematic review. *BMC Infect Dis*. 2013 Nov 11;13(1):534.
45. Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C. Gender-related differences in migraine. *Neurol Sci*. 2020 Dec 1;41(2):429–36.

46. Curran N. Commentary on the influence of gender on the management of chronic pelvic pain. *BJOG Int J Obstet Gynaecol*. 2015;122(6):766–8.
47. Patnaik SS, Laganà AS, Vitale SG, Buttice S, Noventa M, Gizzo S, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. *Arch Gynecol Obstet*. 2017 Jun 1;295(6):1341–59.
48. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. *JAMA*. 2003 Jul 2;290(1):66–72.
49. Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A, et al. The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. *ADHD Atten Deficit Hyperact Disord*. 2017 Mar 1;9(1):47–65.
50. Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. *Eur Neuropsychopharmacol*. 2018 Oct;28(10):1059–88.
51. Larsson H. The importance of selection bias in prospective birth cohort studies. *JCPP Adv*. 2021;1(3):e12043.
52. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. *Am J Epidemiol*. 2017 Nov 1;186(9):1026–34.
53. Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. *Neurosci Biobehav Rev*. 2021 Sep 1;128:789–818.



**Table 1. Descriptive overview of study samples**

	PRS <sub>ADHD</sub> analysis sample	ADHD diagnosis analysis sample	Questionnaire-based ADHD analysis sample*
		Cases/controls	Cases/controls
<b>N</b>	111,261	464 (0.4%)/111,137 (99.6%)	3,556 (8%)/41,152 (92%)
<b>Sex</b>			
<b>Men</b>	38,652 (35%)	283 (61%)/38,616 (35%)	917 (26%)/12,293 (30%)
<b>Women</b>	72,609 (65%)	181 (39%)/72,521 (65%)	2,639 (74%)/28,859 (70%)
<b>Birth year (mean, SD)</b>	1970 (16.5)	1990 (10.3)/1971 (16.5)	1979 (13.3)/1972 (14.1)
<b>Number of ICD-10 diagnoses (mean)</b>	41	48/41	46/39
<b>Education**</b>			
<b>Primary</b>	7,045 (9%)	61 (29%)/7,040 (9%)	198 (7.6%)/1,252(4.2%)
<b>Secondary</b>	38,092 (50%)	109 (52%)/38,261 (50%)	1,225 (45.4%)/16,629 (42.8%)
<b>Higher</b>	31,790 (41%)	41 (19%)/31,763 (41%)	1,239 (47%)/17,507 (53%)
<b>Missing</b>	34,334	253/34,284	894/8,426
<b>Depression diagnosis</b>	19,997 (26%)	98 (46%)***/19,970 (26%)	1,205 (45%)/7,718 (24%)
<b>ADHD diagnosis</b>	0	464	44

Note: \*positive screening; \*\*based on the complete set subset ( $N_{ADHD\ PRS}=76,927$ ;  $N_{ADHD\ diag}=211/77,064$ ;  $N_{ADHD\ ASRS}=2,662/35,388$ ), education was categorised as primary (1-4 grades, 5-9 grades or no education; secondary (10-12 grades and vocational education); higher (university and research degree); \*\*\*data available for 211 participants in the ADHD diagnosis analysis sample and for 2,662 participants who screened positive for ADHD in the questionnaire-based ADHD analysis sample; PRS – polygenic risk score; SD – standard deviation


**Table 2. Associations between PRS<sub>ADHD</sub> and ICD-10 codes after adjustment for multiple testing.**

ICD code	n	OR	lower CI	upper CI	p-value	ICD code name
A56	4,804	1.078	1.047	1.111	6.98E-07	Other sexually transmitted chlamydial diseases
A63	14,384	1.055	1.036	1.075	1.17E-08	Other sexually transmitted diseases
B07	11,535	0.958	0.939	0.977	2.37E-05	Viral warts
B86	3,132	1.111	1.072	1.152	1.02E-08	Scabies
D22	24,852	0.950	0.935	0.963	1.73E-12	Melanocytic naevi
E11	8,102	1.111	1.085	1.139	1.98E-17	Non-insulin-dependent diabetes mellitus
E66	15,121	1.128	1.108	1.148	5.73E-41	Obesity
F06	2,766	1.104	1.062	1.148	6.55E-07	Mental disorders due to brain damage and dysfunction
F07	981	1.176	1.103	1.253	6.22E-07	Behavioural disorders due to brain damage
F10	4,43	1.127	1.093	1.162	2.79E-14	Mental and behavioural disorders due to use of alcohol
F32	25,438	1.061	1.046	1.076	7.85E-16	Depressive episode
F33	8,957	1.059	1.036	1.083	2.91E-07	Recurrent depressive disorder
F41	20,656	1.060	1.044	1.076	1.47E-13	Other anxiety disorders
F43	10,294	1.060	1.039	1.082	2.57E-08	Reaction to severe stress, and adjustment disorders
G43	10,666	1.063	1.041	1.085	6.10E-09	Migraine
G44	18,761	1.053	1.036	1.070	2.92E-10	Other headache syndromes
G47	17,571	1.061	1.044	1.079	4.04E-12	Sleep disorders
G56	12,102	1.075	1.054	1.096	3.52E-13	Mononeuropathies of upper limb
H36	2,179	1.099	1.052	1.149	2.37E-05	Retinal disorders in diseases classified elsewhere
I10	32,483	1.050	1.034	1.066	1.70E-10	Essential (primary) hypertension
I11	24,146	1.063	1.044	1.082	5.27E-11	Hypertensive heart disease
I21	2,244	1.141	1.091	1.194	7.32E-09	Acute myocardial infarction
I25	8,465	1.059	1.031	1.087	2.88E-05	Chronic ischaemic heart disease
I48	6,123	1.077	1.046	1.109	5.03E-07	Atrial fibrillation and flutter
I50	8,996	1.083	1.054	1.112	4.49E-09	Heart failure
I70	3,885	1.082	1.043	1.121	1.92E-05	Atherosclerosis
J03	34,073	1.045	1.031	1.059	1.75E-10	Acute tonsillitis
J04	34,461	1.040	1.027	1.054	3.22E-09	Acute laryngitis and tracheitis
J20	48,302	1.047	1.035	1.060	1.00E-13	Acute bronchitis
J44	4,776	1.148	1.114	1.183	6.35E-17	Other chronic obstructive pulmonary disease
J45	12,409	1.065	1.045	1.086	5.68E-11	Asthma
K04	23,343	1.046	1.030	1.062	3.78E-09	Diseases of pulp and periapical tissues
K05	15,312	1.051	1.033	1.070	1.96E-08	Gingivitis and periodontal diseases
K20	2,282	1.110	1.065	1.158	1.10E-06	Oesophagitis
K21	25,682	1.047	1.032	1.062	3.30E-10	Gastro-oesophageal reflux disease
K25	5,377	1.070	1.041	1.101	2.56E-06	Gastric ulcer
K26	7,097	1.056	1.031	1.083	1.42E-05	Duodenal ulcer
K29	29,638	1.048	1.034	1.063	4.02E-11	Gastritis and duodenitis
K76	4,452	1.075	1.042	1.108	3.88E-06	Other diseases of liver
K80	11,366	1.053	1.032	1.075	6.99E-07	Cholelithiasis
K86	2,517	1.107	1.062	1.153	1.09E-06	Other diseases of pancreas
L02	15,352	1.043	1.026	1.061	1.46E-06	Cutaneous abscess, furuncle and carbuncle
L82	10,797	0.941	0.922	0.961	1.46E-08	Seborrhoeic keratosis
M06	5,231	1.064	1.035	1.095	1.76E-05	Other rheumatoid arthritis
M10	5,648	1.086	1.056	1.117	1.03E-08	Gout

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

M13	12,393	1.048	1.029	1.069	1.16E-06	Other arthritis
M15	15,398	1.094	1.073	1.116	3.30E-19	Polyarthrosis
M16	11,349	1.072	1.049	1.095	2.31E-10	Coxarthrosis [arthrosis of hip]
M17	20,209	1.040	1.023	1.058	6.06E-06	Gonarthrosis [arthrosis of knee]
M19	12,239	1.065	1.044	1.086	6.51E-10	Other arthrosis
M25	37,607	1.042	1.029	1.055	1.48E-10	Other joint disorders, not elsewhere classified
M47	11,483	1.061	1.039	1.083	3.23E-08	Spondylosis
M48	4,395	1.088	1.054	1.123	1.42E-07	Other spondylopathies
M50	9,756	1.072	1.049	1.096	2.08E-10	Cervical disc disorders
M51	19,210	1.064	1.047	1.082	5.15E-14	Other intervertebral disc disorders
M54	67,495	1.082	1.068	1.096	8.09E-35	Dorsalgia
M65	7,097	1.064	1.039	1.091	5.86E-07	Synovitis and tenosynovitis
M70	14,454	1.056	1.037	1.074	2.39E-09	Soft tissue disorders related to use and pressure
M75	18,702	1.061	1.044	1.079	1.49E-12	Shoulder lesions
M77	19,470	1.066	1.049	1.083	5.15E-15	Other enthesopathies
M79	33,221	1.049	1.036	1.063	5.67E-13	Other soft tissue disorders, not elsewhere classified
M96	641	1.208	1.116	1.306	2.53E-06	Postprocedural musculoskeletal disorders
N30	35,670	1.039	1.025	1.054	4.98E-08	Cystitis
N70	5,800	1.066	1.037	1.096	4.96E-06	Salpingitis and ophoritis
N71	3,281	1.096	1.057	1.135	4.88E-07	Inflammatory disease of uterus, except cervix
N76	28,339	1.040	1.024	1.056	5.26E-07	Other inflammation of vagina and vulva
N92	18,806	1.043	1.026	1.061	9.93E-07	Excessive, frequent and irregular menstruation
O00	1,539	1.119	1.063	1.178	1.74E-05	Ectopic pregnancy
O04	8,731	1.102	1.076	1.128	4.56E-16	Medical abortion
O20	6,268	1.069	1.041	1.098	1.12E-06	Haemorrhage in early pregnancy
O23	5,671	1.066	1.037	1.097	8.21E-06	Infections of genitourinary tract in pregnancy
O26	5,444	1.068	1.038	1.099	7.36E-06	Maternal care for conditions related to pregnancy
O47	5,395	1.067	1.037	1.098	1.06E-05	False labour
O99	11,384	1.052	1.030	1.075	2.76E-06	Maternal diseases complicating pregnancy, childbirth
R10	35,274	1.038	1.025	1.052	1.61E-08	Abdominal and pelvic pain
R11	4,388	1.081	1.049	1.115	5.91E-07	Nausea and vomiting
R51	18,544	1.068	1.051	1.085	1.70E-15	Headache
R73	6,301	1.068	1.041	1.097	7.47E-07	Elevated blood glucose level
T51	1,066	1.154	1.085	1.226	4.53E-06	Toxic effect of alcohol
Z95	3,722	1.088	1.050	1.128	3.80E-06	Presence of cardiac and vascular implants and grafts

Figure 1. Associations between PRS<sub>ADHD</sub> and ICD-10 codes



Note: The X axis indicates groups of ICD10 main codes coloured respectively and Y axis  $-\log_{10}$  of the p values. Each triangle in the plot represents one ICD-10 main code and the direction of the triangle represents direction of effect. Red line—Bonferroni-corrected significance level ( $3.3 \times 10^{-5}$ ). Phenotypes passed the Bonferroni correction from the lowest to highest p-values: E66-obesity; M54-dorsalgia; M15-polyarthrosis; J44-chronic obstructive pulmonary diseases; E11-non-insulin dependent diabetes; O04-medical abortion; F32-depressive episode; R51-headache; M77-other enthesopathies; F10-mental and behavioural disorders due to use of alcohol; M51-other intervertebral disc disorders; J20-acute bronchitis; F41-other anxiety disorders; G56-mononeuropathies of upper limb; M79-other soft tissue disorders; M75-shoulder lesion; D22-melanocytic naevi; G47-sleep disorders; K29-gastritis and duodenitis; I11-hypertensive heart disease; J45-asthma; M25-other joint disorders; I10-primary hypertension; J03-acute tonsillitis; M50-cervical disc disorders; M16-coxarthrosis; G44-other headache syndromes; K21-gastro-oesophageal reflux disease; M19-other arthrosis; M70-soft tissue disorders related to use, overuse and pressure; J04-acute laryngitis and tracheitis; K04-diseases of pulp and periapical tissues; I50-heart failure; G43-migraine; I21-acute myocardial infarction; B86-scabies; M10-gout; A63-other predominantly sexually transmitted diseases; L82-seborrhoeic keratosis; R10-abdominal and pelvic pain; K05-gingivitis and periodontal diseases; F43-reaction to severe stress; M47-spondylosis; N30-cystitis; M48-other spondylopathies; F33-recurrent depressive disorder; N71-inflammatory disease of uterus; I48-atrial inflammation of vagina and vulva; M65-synovitis and tenosynovitis; R11-nausea and vomiting; F07-personality and behavioural disorders due to brain damage; F06-other mental disorders due to brain damage; A56-other sexually transmitted chlamydial diseases; K80-cholelithiasis; R73-elevated blood glucose level; N92-excessive, frequent and irregular menstruation; K86-other diseases of pancreas; K20-oesophagitis; O20-haemorrhage in early pregnancy; M13-other arthritis; L02-cutaneous abscess, furuncle and carbuncle; M96-postprocedural musculoskeletal disorders; K25-gastric ulcer; O99-other maternal diseases; Z95-presence of cardiac and vascular implants and grafts; K76-other diseases of liver; T51-toxic effect of alcohol; N70-salpingitis and oophoritis; M17-gonarthrosis; O26-maternal care for other conditions related to pregnancy; O23-infections of genitourinary tract in pregnancy; O47-false labour; K26-duodenal ulcer; O00-ectopic pregnancy; M06-other rheumatoid arthritis; I70-atherosclerosis; H36-retinal disorders in diseases classified elsewhere; B07-viral warts; I25-chronic ischaemic heart disease

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Figure 2. Comparison of associations between top vs bottom and top vs medium PRS<sub>ADHD</sub> risk on ICD-10 codes after adjustment for multiple testing.**



Note: PRS – polygenic risk score; 95% CI – 95% confidence intervals;

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Figure 3. Comparison of associations between high PRS<sub>ADHD</sub> risk and ICD-10 codes in females and males.**



Note: PRS – polygenic risk score; 95% CI – 95% confidence intervals; ICD-10 codes less than 10 cases were excluded from analyses

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Figure 4. Comparison of associations between ADHD diagnosis and questionnaire-based ADHD on ICD-10 codes after adjustment for multiple testing.**



Note: PRS – polygenic risk score; 95% CI – 95% confidence intervals; ICD-10 codes less than 10 cases were excluded from analyses